Yon Su Kim

Yon Su Kim

Auto-generated profile, based on publicly available information

Yon Su Kim

Division of Nephrology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2012 in Critical Care
Verified
Journal Article
Open access
PDF file
JAJung Nam An
Jung Nam An
JLJung Pyo Lee
Jung Pyo Lee
HJHee Jung Jeon
Hee Jung Jeon
DKDo Hyoung Kim
Do Hyoung Kim
YOYun Kyu Oh
Yun Kyu Oh
CLChun Soo Lim
Chun Soo Lim
Introduction: Severe hyperkalemia, with potassium (K+) levels ≥ 6.5 mEq/L, is a potentially life-threatening electrolyte imbalance. For prompt and effective treatment, it is important to know its risk factors, clinical manifestations, and predictors of mortality. Methods: An observational cohort study was performed at 2 medical centers. A total of 923 consecutive Korean patients were analyzed. All were 19 years of age or older and were hospitalized with severe hyperkalemia between August 2007 and July 2010; the diagnosis of severe hyperkalemia was made either at the time of admission to the hospital or during the period of hospitalization. Demographic and baseline clinical characteristics at the time of hyperkalemia diagnosis were assessed, and clinical outcomes such as in-hospital mortality were reviewed, using the institutions' electronic medical record systems. Results: Chronic kidney disease (CKD) was the most common underlying medical condition, and the most common precipitating factor of hyperkalemia was metabolic acidosis. Emergent admission was indicated in 68.6% of patients, 36.7% had electrocardiogram findings typical of hyperkalemia, 24.5% had multi-organ failure (MOF) at the time of hyperkalemia diagnosis, and 20.3% were diagnosed with severe hyperkalemia at the time of cardiac arrest. The in-hospital mortality rate was 30.7%; the rate was strongly correlated with the difference between serum K+ levels at admission and at their highest point, and with severe medical conditions such as malignancy, infection, and bleeding. Furthermore, a higher in-hospital mortality rate was significantly associated with the presence of cardiac arrest and/or MOF at the time of diagnosis, emergent admission, and intensive care unit treatment during hospitalization. More importantly, acute kidney injury (AKI) in patients with normal baseline renal function was a strong predictor of mortality, compared with AKI superimposed on CKD. Conclusions: Severe hyperkalemia occurs in various medical conditions; the precipitating factors are similarly diverse. The mortality rate is especially high in patients with severe underlying disease, coexisting medical conditions, and those with normal baseline renal function.

15 June 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SRSeungwon Ryu
Seungwon Ryu
JSJae Woo Shin
Jae Woo Shin
SKSoie Kwon
Soie Kwon
JLJiwon Lee
Jiwon Lee
Yong-Lim KimYong-Lim Kim
Yong-Lim Kim
HKHye Young Kim
Hye Young Kim
The roles of neutrophils in renal inflammation are currently unclear. On examining these cells in the unilateral ureteral obstruction murine model of chronic kidney disease, we found that the injured kidney bore a large and rapidly expanding population of neutrophils that expressed the eosinophil marker Siglec-F. We first verified that these cells were neutrophils. Siglec-F+ neutrophils were recently detected in several studies in other disease contexts. We then showed that a) these cells were derived from conventional neutrophils in the renal vasculature by TGF-β1 and GM-CSF; b) they differed from their parent cells by more frequent hypersegmentation, higher expression of profibrotic inflammatory cytokines, and notably, expression of collagen 1; and c) their depletion reduced collagen deposition and disease progression, but adoptive transfer increased renal fibrosis. These findings have thus unveiled a subtype of neutrophils that participate in renal fibrosis and a potentially new therapeutic target in chronic kidney disease.

21 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KYKyung Don Yoo
Kyung Don Yoo
JNJunhyug Noh
Junhyug Noh
HLHajeong Lee
Hajeong Lee
DKDong Ki Kim
Dong Ki Kim
CLChun Soo Lim
Chun Soo Lim
YKYon Su Kim
Yon Su Kim
Accurate prediction of graft survival after kidney transplant is limited by the complexity and heterogeneity of risk factors influencing allograft survival. In this study, we applied machine learning methods, in combination with survival statistics, to build new prediction models of graft survival that included immunological factors, as well as known recipient and donor variables. Graft survival was estimated from a retrospective analysis of the data from a multicenter cohort of 3,117 kidney transplant recipients. We evaluated the predictive power of ensemble learning algorithms (survival decision tree, bagging, random forest, and ridge and lasso) and compared outcomes to those of conventional models (decision tree and Cox regression). Using a conventional decision tree model, the 3-month serum creatinine level post-transplant (cut-off, 1.65 mg/dl) predicted a graft failure rate of 77.8% (index of concordance, 0.71). Using a survival decision tree model increased the index of concordance to 0.80, with the episode of acute rejection during the first year post-transplant being associated with a 4.27-fold increase in the risk of graft failure. Our study revealed that early acute rejection in the first year is associated with a substantially increased risk of graft failure. Machine learning methods may provide versatile and feasible tools for forecasting graft survival.

1 January 2010 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
CLChung Sik Lee
Chung Sik Lee
RCRan-Hui Cha
Ran-Hui Cha
YLYoun-Hee Lim
Youn-Hee Lim
HKHo Kim
Ho Kim
KSKa Heon Song
Ka Heon Song
YKYon Su Kim
Yon Su Kim
Lee CS, et al. J Korean Med Sci. 2010 Nov;25(11):1616-1625. http://dx.doi.org/10.3346/jkms.2010.25.11.1616

1 April 2016 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
RCRan-Hui Cha
Ran-Hui Cha
SKShin Wook Kang
Shin Wook Kang
CPCheol Whee Park
Cheol Whee Park
DCDae Ryong Cha
Dae Ryong Cha
KNKi Young Na
Ki Young Na
YKYon Su Kim
Yon Su Kim
Background and objectives The notion that oral intestinal sorbent AST-120 slows renal disease progression has not been evaluated thoroughly. In this study, we investigated the long-term effect of AST-120 on renal disease progression (doubling of serum creatinine, eGFR decrease >50%, or initiation of RRT) in patients with advanced CKD. Design, setting, participants, & measurements We prospectively recruited 579 patients (CKD stage 3 or 4) from 11 medical centers in Korea from March 4, 2009 to August 31, 2010 and randomized them into an AST-120 arm and a control arm. Patients in the AST-120 arm were given 6 g AST-120 in three divided doses per day, and those in the control arm received only standard conventional treatment (open-label design) for 36 months or until the occurrence of primary outcomes. Results Levels of serum and urine indoxyl sulfate and β2-microglobulin decreased throughout the study period in both treatment arms; however, there was not a significant difference in change in uremic toxins in the AST-120 and control arms. The two arms were not different in the occurrence of composite primary outcomes (100 events in 272 individuals in the AST-120 arm and 100 events in 266 individuals in the control arm; hazard ratio, 1.12; 95% confidence interval, 0.85 to 1.48; log-rank P=0.45). The decline in eGFR and change in proteinuria were similar in the two treatment arms over time (Prandomization–time=0.64 and Prandomization–time=0.16, respectively). There was no difference in mortality (nine deaths in the AST-120 arm and 11 deaths in the control arm; log-rank P=0.73) or unplanned hospitalizations (102 in the AST-120 arm and 109 in the control arm; log-rank P=0.76) in the two treatment arms. There was no significant difference of the health–related quality of life score between the two arms. Conclusions Long-term use of AST-120 added to standard treatment did not change renal disease progression, proteinuria, mortality, and health–related quality of life in patients with advanced renal dysfunction.

1 June 2010 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
SKSun Moon Kim
Sun Moon Kim
RCRan-Hui Cha
Ran-Hui Cha
JLJung Pyo Lee
Jung Pyo Lee
DKDong Ki Kim
Dong Ki Kim
KOKook-Hwan Oh
Kook-Hwan Oh
YKYon Su Kim
Yon Su Kim